

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM2/17 - Therapeutic Drugs

Dead line: 13.10.2017

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability										
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}			
Set of samples 1																	
(81) Digoxin					128			0				128	127	99%			
Samples and groups		[nmol/L]															
Sample A1		2,14	0,28	13	128			0	CRV	2,141	0,021	36%	1,37	2,92	128	127	99%
(1) Abbott		1,80	0,13	7,2	33	0									33		
(12) Beckman Coulter		2,28	0,12	5,0	13	0									13		
(29) Siemens (DPC)		2,25	0,22	9,6	8	0									8		
(58) Beckman Coulter (Olympus)		2,32	0,17	7,2	11	0									11		
(60) Roche		2,15	0,19	8,6	37	0									37		
(179) Siemens (Bayer)		2,39	0,18	7,5	18	0									18		
Other					8	0									8		
										1x 15, 3x 149, 2x 166, 2x 177							
Sample B1		2,54	0,31	12	128			0	CRV	2,555	0,030	36%	1,63	3,48	128	127	99%
(1) Abbott		2,19	0,13	5,9	33	0									33		
(12) Beckman Coulter		2,73	0,15	5,4	13	0									13		
(29) Siemens (DPC)		2,58	0,39	15	8	0									8		
(58) Beckman Coulter (Olympus)		2,75	0,24	8,6	11	0									11		
(60) Roche		2,57	0,19	7,3	37	0									37		
(179) Siemens (Bayer)		2,82	0,12	4,1	18	0									18		
Other					8	0									8		
										1x 15, 3x 149, 2x 166, 2x 177							
(82) Theophylline					89			0				89	88	99%			
Samples and groups		[µmol/L]															
Sample A1		109	7,8	7,2	89			0	CRV	110,8	1,1	24%	84,2	138	89	89	100%
(1) Abbott		105	6,3	6,0	23	0									23		
(12) Beckman Coulter		103	6,6	6,5	7	0									7		
(29) Siemens (DPC)		114	11	9,7	7	0									7		
(58) Beckman Coulter (Olympus)		104	9,3	8,9	8	0									8		
(60) Roche		111	4,7	4,2	28	0									28		
(179) Siemens (Bayer)		117	4,0	3,4	11	0									11		
Other					5	0									5		
										1x 149, 3x 166, 1x 177							
Sample B1		66,1	4,9	7,5	89			0	CRV	66,94	0,67	24%	50,8	83,1	89	88	99%
(1) Abbott		65,4	5,1	7,9	23	0									23		
(12) Beckman Coulter		61,2	3,6	5,9	7	0									7		
(29) Siemens (DPC)		67,5	13	19	7	0									7		
(58) Beckman Coulter (Olympus)		62,9	6,3	10	8	0									8		
(60) Roche		66,7	2,7	4,1	28	0									28		
(179) Siemens (Bayer)		72,7	6,3	8,7	11	0									11		
Other					5	0									5		
										1x 149, 3x 166, 1x 177							

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM2/17 - Therapeutic Drugs

Dead line: 13.10.2017

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(83) Primidone					9							9	9	100%							0		
Samples and groups	[µmol/L]																						
Sample A1		47,8	4,1	8,5	9	CVP	47,8	5,0	24%	36,3	59,3	9	9	100%							0		
(999) another manufacturer		49,0	2,6	5,4	6							6											
Other					3							3											
						1x 60, 2x 118																	
Sample B1		43,9	4,4	10	9	CVP	43,9	5,5	24%	33,3	54,5	9	9	100%							0		
(999) another manufacturer		44,5	4,0	9,1	6							6											
Other					3							3											
						1x 60, 2x 118																	
(84) Phenobarbital					28							28	28	100%							0		
Samples and groups	[µmol/L]																						
Sample A1		64,5	4,7	7,4	28	CVP	64,5	2,2	20%	51,6	77,4	28	28	100%							0		
(1) Abbott		65,7	4,8	7,2	11							11											
(60) Roche		62,5	3,3	5,3	9							9											
Other					8							8											
						2x 58, 1x 118, 1x 179, 4x 999																	
Sample B1		95,3	6,3	6,6	28	CVP	95,3	2,9	20%	76,2	115	28	28	100%							0		
(1) Abbott		97,7	6,1	6,3	11							11											
(60) Roche		91,8	2,7	2,9	9							9											
Other					8							8											
						2x 58, 1x 118, 1x 179, 4x 999																	
(85) Phenytoin					46							46	45	98%							0		
Samples and groups	[µmol/L]																						
Sample A1		61,8	4,1	6,6	46	CVP	61,8	1,5	20%	49,4	74,2	46	46	100%							0		
(1) Abbott		63,3	2,7	4,3	13							13											
(60) Roche		60,1	2,0	3,4	14							14											
Other					19							19											
						1x 4, 2x 12, 3x 29, 3x 58, 1x 118, 1x 149, 1x 166, 3x 179, 4x 999																	
Sample B1		53,6	2,6	4,9	46	CVP	53,6	0,95	20%	42,8	64,4	46	45	98%							0		
(1) Abbott		53,3	2,6	4,9	13							13											
(60) Roche		53,5	2,1	3,9	14							14											
Other					19							19											
						1x 4, 2x 12, 3x 29, 3x 58, 1x 118, 1x 149, 1x 166, 3x 179, 4x 999																	
(86) Carbamazepin					65							65	60	92%							0		
Samples and groups	[µmol/L]																						
Sample A1		9,32	0,99	11	65	CVP	9,32	0,30	20%	7,45	11,2	65	60	92%							0		
(1) Abbott		9,33	0,60	6,5	20							20											
(29) Siemens (DPC)		8,68	0,77	8,9	6							6											
(60) Roche		9,06	1,1	12	18							18											
(179) Siemens (Bayer)		10,0	0,89	8,9	6							6											
Other					15							15											
						1x 4, 1x 9, 2x 12, 4x 58, 1x 118, 1x 149, 1x 166, 4x 999																	
Sample B1		26,2	1,9	7,3	65	CVP	26,2	0,58	20%	20,9	31,5	65	64	98%							0		
(1) Abbott		25,6	1,3	5,1	20							20											
(29) Siemens (DPC)		24,6	2,3	9,4	6							6											
(60) Roche		26,0	1,2	4,5	18							18											
(179) Siemens (Bayer)		29,0	3,4	12	6							6											

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM2/17 - Therapeutic Drugs

Dead line: 13.10.2017

Test	[unit]	Comparability						Traceability																		
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}				
(86) Carbamazepin	[µmol/L]				65							65	60	92%									0			
Samples and groups																										
Sample B1		26,2	1,9	7,3	65		CVP	26,2	0,58	20%	20,9	31,5	65	64	98%									0		
Other					15	0	1x 4, 1x 9, 2x 12, 4x 58, 1x 118, 1x 149, 1x 166, 4x 999										15									
(87) Ethosuximide	[µmol/L]				9								9	8	89%									0		
Samples and groups																										
Sample A1		577	61	11	9		CVP	577	75	24%	438	716	9	9	100%									0		
(999) another manufacturer		592	84	14	6	0											6									
Other					3	0	2x 118, 1x 179										3									
Sample B1		192	18	9,4	9		CVP	192	22	24%	145	239	9	8	89%									0		
(999) another manufacturer		191	20	10	6	0											6									
Other					3	0	2x 118, 1x 179										3									
(88) Valproic acid	[µmol/L]				84								84	82	98%									0		
Samples and groups																										
Sample A1		216	17	7,8	84		CVP	216	4,5	20%	172	260	84	82	98%									0		
(1) Abbott		204	15	7,2	23	0											23									
(29) Siemens (DPC)		215	11	5,2	8	0											8									
(58) Beckman Coulter (Olympus)		235	25	11	7	0											7									
(60) Roche		216	8,6	4,0	27	0											27									
(179) Siemens (Bayer)		231	16	6,9	11	0											11									
Other					8	0	1x 0, 1x 4, 3x 12, 2x 149, 1x 166										8									
Sample B1		536	34	6,3	84		CVP	536	9,0	20%	428	644	84	83	99%									0		
(1) Abbott		503	34	6,7	23	0											23									
(29) Siemens (DPC)		541	16	2,9	8	0											8									
(58) Beckman Coulter (Olympus)		588	39	6,7	7	0											7									
(60) Roche		540	17	3,1	27	0											27									
(179) Siemens (Bayer)		545	24	4,5	11	0											11									
Other					8	0	1x 0, 1x 4, 3x 12, 2x 149, 1x 166										8									
Set of samples 2																										
(89) Amicacin	[µmol/L]				29								29	26	90%									0		
Samples and groups																										
Sample A2		4,60	0,96	21	29		CVP	4,6	0,44	42%	2,66	6,54	29	27	93%									0		
(60) Roche		4,38	0,76	17	17	0											17									
Other					12	0	4x 1, 1x 4, 3x 12, 2x 58, 1x 149, 1x 166										12									
Sample B2		24,9	1,5	6,2	29		CVP	24,9	0,70	20%	19,9	29,9	29	28	97%									0		
(60) Roche		24,5	1,1	4,3	17	0											17									
Other					12	0	4x 1, 1x 4, 3x 12, 2x 58, 1x 149, 1x 166										12									
(90) Gentamicin	[µmol/L]				55								55	54	98%									0		
Samples and groups																										
Sample A2		13,0	1,7	13	55		CVP	13	0,55	31%	8,97	17,1	55	54	98%									0		

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM2/17 - Therapeutic Drugs

Dead line: 13.10.2017

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(90) Gentamicin					55							55	54	98%									0
Samples and groups	[µmol/L]																						
Sample A2		13,0	1,7	13	55	CVP	13	0,55	31%	8,97	17,1	55	54	98%									0
(1) Abbott		13,5	1,3	9,4	21							21											
(60) Roche		11,8	1,4	12	19							19											
(179) Siemens (Bayer)		13,8	0,59	4,3	9							9											
Other					6							6											
							1x 4, 3x 12, 2x 58																
Sample B2		9,61	1,1	12	55	CVP	9,61	0,38	31%	6,63	12,6	55	55	100%									0
(1) Abbott		9,95	0,84	8,4	21							21											
(60) Roche		8,73	1,0	11	19							19											
(179) Siemens (Bayer)		9,80	0,30	3,1	9							9											
Other					6							6											
							1x 4, 3x 12, 2x 58																
(92) Vankomycin					56							56	56	100%									0
Samples and groups	[µmol/L]																						
Sample A2		25,0	3,1	13	56	CVP	25	1,0	28%	18	32	56	56	100%									0
(1) Abbott		25,2	1,4	5,4	21							21											
(60) Roche		26,9	3,3	12	21							21											
(179) Siemens (Bayer)		20,4	1,5	7,2	9							9											
Other					5							5											
							1x 4, 2x 12, 1x 58, 1x 149																
Sample B2		10,8	1,3	12	56	CVP	10,8	0,42	28%	7,77	13,9	56	56	100%									0
(1) Abbott		11,0	0,59	5,3	21							21											
(60) Roche		11,5	1,0	9,1	21							21											
(179) Siemens (Bayer)		8,46	0,34	4,0	9							9											
Other					5							5											
							1x 4, 2x 12, 1x 58, 1x 149																
(93) Methotrexate					13							13	11	85%									0
Samples and groups	[µmol/L]																						
Sample A2		9,13	1,2	13	13	CVP	9,13	0,80	30%	6,39	11,9	13	12	92%									0
(1) Abbott		8,96	1,1	12	9							9											
Other					4							4											
							1x 4, 1x 60, 1x 166, 1x 999																
Sample B2		0,421	0,03	7,6	13	CVP	0,421	0,022	30%	0,294	0,548	13	12	92%									0
(1) Abbott		0,419	0,01	4,2	9							9											
Other					4							4											
							1x 4, 1x 60, 1x 166, 1x 999																

st_kn_np

End of report

Printed: 19.10.2017